{"classes":[{"categories":[{"measurements":[{"comment":"Upper confidence interval bounds were not estimable due to censoring","groupId":"OG002","lowerLimit":"12.286","upperLimit":"NA","value":"25.6"},{"comment":"Median and confidence intervals were not etimable due to censoring","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"1"}],"units":"Participants"}],"description":"DoR was measured from the first CR/PR (whichever was first recorded) until the first date of progressive disease.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who received afamitresgene autoleucel 0.1x10\\^9 transduced cells","id":"OG000","title":"Afamitresgene Autoleucel, Group 1"},{"description":"Participants who received afamitresgene autoleucel 0.5-1.2x10\\^9 transduced cells","id":"OG001","title":"Afamitresgene Autoleucel, Group 2"},{"description":"Participants who received afamitresgene autoleucel 1.2-10x10\\^9 transduced cells","id":"OG002","title":"Afamitresgene Autoleucel Group 3 + Expansion"},{"description":"Participants who received LDR in combination with lymphodepletion chemotherapy followed by the afamitresgene autoleucel infusion (1.2-10x10\\^9 transduced cells).","id":"OG003","title":"Substudy: Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel"}],"paramType":"MEAN","populationDescription":"No patients in Groups 1 and 2 achieved objective response.","reportingStatus":"POSTED","timeFrame":"From initial confirmed response (DR or PR) until PD or censored date. is defined as all participants who had not experienced the event of interest (i.e. ongoing, event free) at the time of the data cut off (used for the analysis).","title":"Duration of Response (DoR)","type":"SECONDARY","unitOfMeasure":"Weeks"}